Adverse events with oral GLP-1 RA Similar to injectable GLP-1 RA, the most common AE with oral GLP-1 RA were gastrointestinal which were mild to moderate in severity (Tables 2 and 3, safety outcomes)
[PubMed | ClinicalTrials.gov | DOI] Wadden TA, Bailey TS, Billings LK, et al
The baseline remains 12 weeks across the activation, remodeling, and maintenance phases
Each tablet contains a precisely measured 500 mcg dose for accurate, reproducible in vitro and in vivo research applications
Common symptoms during this withdrawal phase are: Nausea, vomiting, and diarrhea Severe cravings for opioids Sweating and chills Flu-like symptoms such as fever, body aches, and fatigue Increased heart rate and blood pressure Mood changes, including depression, anxiety, or hopelessness Last Stage: Gradual Improvement For many people, physical withdrawal symptoms begin to gradually get better after 7-10 days